Inhibrx, Inc.(INBX) Stock Research - Grey Stern Research

Inhibrx, Inc. (INBX) Stock Analysis

$14.88 (-3.38%)

INBX Financial Performance


Use the table below to view Inhibrx, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $15.40 -
52 Week Low $10.80 -
52 Week High $18.95 -
Market Cap $222.9 Million 14/18
Gross Margin -100% 17/18
Profit Margin 100% 1/18
EBITDA margin -160423% 17/18
Q2 - 2024 Revenue $100,000 8/18
Q2 - 2024 Earnings $1.9 Billion 1/18
Q2 - 2024 Free Cash Flow -$58.6 Billion 18/18
Trailing 4 Quarters Revenue $1.9 Million 7/18
Trailing 4 Quarters Earnings $1.6 Billion 1/18
Quarterly Earnings Growth 4049% 1/18
Annual Earnings Growth 946% 1/18
Quarterly Revenue Growth 233% 2/18
Annual Revenue Growth 2188% 1/18
Cash On Hand $226.9 Million 5/18
Short Term Debt $2.2 Million 9/18
Long Term Debt $0 12/18

Inhibrx, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Inhibrx, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 0.14 2/18
PS 120.31 6/18
PB 1.02 13/18
PC 0.98 15/18
Liabilities to Equity 0.18 7/18
ROA 6.32 1/18
ROE 7.45 1/18
Current Ratio 6.62 12/18
Quick Ratio 5.81 11/18
Long Term Debt to Equity 0.00 12/18
Debt to Equity 0.01 13/18
Burn Rate -0.12 18/18
Cash to Cap 1.02 4/18
CCR -0.03 16/18
EV to EBITDA 0.01 2/18
EV to Revenue -0.95 11/18

Company Details

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

CEO: Mr. Mark Paul Lappe

Website: https://inhibrx.com

Address: 11025 North Torrey Pines Road La Jolla, CA

Exchange: NASDAQ Global Market

Industry: Biotechnology

Inhibrx, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Inhibrx, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Protagonist Therapeutics, Inc. PTGX $2.6 Billion
Merrimack Pharmaceuticals, Inc. MACK $224.0 Million
Merus N.V. MRUS $3.4 Billion
Celcuity Inc. CELC $543.2 Million
Crinetics Pharmaceuticals, Inc. CRNX $4.3 Billion
Stoke Therapeutics, Inc. STOK $641.8 Million
Larimar Therapeutics, Inc. LRMR $401.3 Million
Kronos Bio, Inc. KRON $60.2 Million
Ikena Oncology, Inc. IKNA $81.1 Million
Design Therapeutics, Inc. DSGN $281.4 Million
Viridian Therapeutics, Inc. VRDN $1.9 Billion
Werewolf Therapeutics, Inc. HOWL $88.3 Million
Lyell Immunopharma, Inc. LYEL $314.9 Million
Monte Rosa Therapeutics, Inc. GLUE $330.8 Million
Eliem Therapeutics, Inc. ELYM $342.7 Million
DICE Therapeutics, Inc. DICE $2.3 Billion
Anebulo Pharmaceuticals, Inc. ANEB $51.3 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
INBX Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 100,000 $1.9 Billion
Q1 2024 $ 0 -$78.7 Million
Q4 2023 $ 1.6 Million -$93.6 Million
Q3 2023 $ 119,000 -$51.8 Million
Q2 2023 $ 30,000 -$47.1 Million
Q1 2023 $ 17,000 -$48.7 Million
Q4 2022 $ 274,000 -$40.9 Million
Q3 2022 $ 278,000 -$35.3 Million

View All

INBX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $226.9 Million $258.4 Million $2.2 Million $219.4 Million
Q1 2024 $252.5 Million $288.6 Million $210.9 Million $11.6 Million
Q4 2023 $277.9 Million $307.9 Million $210.1 Million $43.5 Million
Q3 2023 $337.3 Million $372.7 Million $205.7 Million $129.6 Million
Q2 2023 $192.5 Million $213.2 Million $208.6 Million -$24.8 Million
Q1 2023 $234.3 Million $253.7 Million $203.3 Million $15.1 Million
Q4 2022 $273.9 Million $290.9 Million $202.1 Million $58.1 Million
Q3 2022 $146.1 Million $164.9 Million $176.3 Million -$35.1 Million

View All

INBX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 -$58.6 Million -$1.2 Million -$25.6 Million
Q1 2024 -$64.2 Million -$1.1 Million -$25.4 Million
Q4 2023 -$60.3 Million -$3.4 Million -$59.4 Million
Q3 2023 -$55.1 Million -$811,000 $144.8 Million
Q2 2023 -$42.6 Million -$317,000 -$41.8 Million
Q1 2023 -$40.0 Million -$23,000 -$39.6 Million
Q4 2022 -$30.9 Million -$267,000 $127.8 Million
Q3 2022 -$85.1 Million -$419,000 -$30.3 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions